Treatment of multiple myeloma (MM) is now very complex and costly. However, survival benefits achieved with new therapies in clinical trials are not being seen in clinical practice, in part because many MM patients stop therapy early, often due to side-effects.
The MY-PROMPT-2 trial tests whether real-time symptom feedback using patient-reported outcome measures improves duration on treatment, leading to better patient outcomes and more efficient use of these high-cost medicines.
MY-PROMPT-2 is a collaboration between the Transfusion Research Unit (TRU) at Monash University and AMaRC.
Trial Management Centre: Transfusion Research Unit, Monash University
Recruitment updated as of October 2023
A parallel, non-blinded, multicentre, Bayesian randomised control trial
Qualitative Interview Sub-Study
This sub-study will explore patient, clinician, and hospital staff's experience of the trial and the intervention.
Economic Evaluation Sub-Study
This sub-study will look to determine the cost-effectiveness of real-time feedback of patient-reported outcome measures.
TRIAL PRINCIPAL INVESTIGATORS
Coordinating Principal Investigator: Professor Andrew Spencer, Monash University & AMaRC
Dr Sueh-li Lim, Alfred Health
2023 – 2027
Patients with relapsed multiple myeloma receiving standard-of-care treatment (daratumumab, lenalidomide, or carfilzomib based therapies) who are registered on the MRDR.